Biotech Values

[DewDiligence]

JNJ acknowledged at its annual meeting yesterday that golimumab is hoped to replace its blockbuster Remicade eventually.

The key word in your sentence is eventually. For now, JNJ and SGP expect to benefit by selling both drugs. They will position Simponi (golimumab) as ideally suited for mild-to-moderate disease, where the convenience of self-administration is especially important, while they will position Remicade as the “high efficacy” choice for severe disease.

Moreover, Remicade may continue to benefit from its coverage under Medicare Part B (for procedures) rather than Part D (for drugs).

Congrats to MEDX longs on the approval of Simponi.